I'm LongbridgeAI, I can summarize articles.TransMedics Group Inc. reported significant financial growth, with FY25 revenue reaching USD 605 million and adjusted operating profit turning positive at USD 112.2 million. The company forecasts FY26 revenue between USD 737–757 million, reflecting 22–25% growth. Holding USD 472.7 million in cash as of June 2026, TransMedics plans to expand its OCS Kidney platform, European operations, and OCS 3.0 technology.
- Transmedics Group Inc. menegaskan strategi memperluas pemanfaatan organ transplant lewat platform perfusi hangat portabel OCS dan jaringan layanan NOP. * Pendapatan naik menjadi USD 605 juta pada FY25 dari USD 94 juta pada FY22; CAGR pendapatan FY22–FY25 sebesar 86%. * Laba operasi disesuaikan berbalik positif menjadi USD 112,2 juta pada FY25; FY24 USD 37 juta, FY23 rugi USD 29 juta. * Perusahaan memandu pendapatan FY26 USD 737–757 juta, setara pertumbuhan 22–25%. * Kas dan setara kas tercatat USD 472,7 juta per 30 Juni 2026; fokus pertumbuhan mencakup OCS Kidney, ekspansi Eropa, dan OCS 3.0. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transmedics Group Inc. published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here